Literature DB >> 20064512

SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease.

Jeffrey B Schwimmer1, Winston Dunn, Gregory J Norman, Perrie E Pardee, Michael S Middleton, Nanda Kerkar, Claude B Sirlin.   

Abstract

BACKGROUND & AIMS: The appropriate alanine aminotransferase (ALT) threshold value to use for diagnosis of chronic liver disease in children is unknown. We sought to develop gender-specific, biology-based, pediatric ALT thresholds.
METHODS: The Screening ALT for Elevation in Today's Youth (SAFETY) study collected observational data from acute care children's hospitals, the National Health and Nutrition Examination Survey (NHANES, 1999-2006), overweight children with and without non-alcoholic fatty liver disease (NAFLD), and children with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. The study compared the sensitivity and specificity of ALT thresholds currently used by children's hospitals vs study-derived, gender-specific, biology-based, ALT thresholds for detecting children with NAFLD, HCV, or HBV.
RESULTS: The median upper limit of ALT at children's hospitals was 53 U/L (range, 30-90 U/L). The 95th percentile levels for ALT in healthy weight, metabolically normal, liver disease-free, NHANES pediatric participants were 25.8 U/L (boys) and 22.1 U/L (girls). The concordance statistics of these NHANES-derived thresholds for liver disease detection were 0.85 (95% confidence interval [CI]: 0.74-0.96) in boys and 0.91 (95% CI: 0.83-0.99) in girls for NAFLD, 0.80 (95% CI: 0.70-0.91) in boys and 0.79 (95% CI: 0.69-0.89) in girls for HBV, and 0.86 (95% CI: 0.77-0.95) in boys and 0.84 (95% CI: 0.75-0.93) in girls for HCV. Using current children's hospitals ALT thresholds, the median sensitivity for detection of NAFLD, HBV, and HCV ranged from 32% to 48%; median specificity was 92% (boys) and 96% (girls). Using NHANES-derived thresholds, the sensitivities were 72% (boys) and 82% (girls); specificities were 79% (boys) and 85% (girls).
CONCLUSIONS: The upper limit of ALT used in children's hospitals varies widely and is set too high to reliably detect chronic liver disease. Biology-based thresholds provide higher sensitivity and only slightly less specificity. Clinical guidelines for use of screening ALT and exclusion criteria for clinical trials should be modified. 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  clinical trials; hepatitis; nonalcoholic fatty liver disease; obesity; patient safety

Mesh:

Substances:

Year:  2010        PMID: 20064512      PMCID: PMC2846968          DOI: 10.1053/j.gastro.2009.12.052

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  25 in total

1.  Hepatic fat fraction: MR imaging for quantitative measurement and display--early experience.

Authors:  Hero K Hussain; Thomas L Chenevert; Frank J Londy; Vikas Gulani; Scott D Swanson; Barbara J McKenna; Henry D Appelman; Saroja Adusumilli; Joel K Greenson; Hari S Conjeevaram
Journal:  Radiology       Date:  2005-10-19       Impact factor: 11.105

Review 2.  Drug-related hepatotoxicity.

Authors:  Victor J Navarro; John R Senior
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

3.  Serum leptin levels in patients with nonalcoholic steatohepatitis.

Authors:  A Uygun; A Kadayifci; Z Yesilova; A Erdil; H Yaman; M Saka; M S Deveci; S Bagci; M Gulsen; N Karaeren; K Dagalp
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

Review 4.  Children with hepatitis C.

Authors:  Maureen M Jonas
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

5.  Simple proton spectroscopic imaging.

Authors:  W T Dixon
Journal:  Radiology       Date:  1984-10       Impact factor: 11.105

6.  Outcome and prognostic markers in severe drug-induced liver disease.

Authors:  Einar Björnsson; Rolf Olsson
Journal:  Hepatology       Date:  2005-08       Impact factor: 17.425

7.  Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease.

Authors:  Jeffrey B Schwimmer; Reena Deutsch; Jeffrey B Rauch; Cynthia Behling; Robert Newbury; Joel E Lavine
Journal:  J Pediatr       Date:  2003-10       Impact factor: 4.406

8.  Drug-induced liver injury: summary of a single topic clinical research conference.

Authors:  Paul B Watkins; Leonard B Seeff
Journal:  Hepatology       Date:  2006-03       Impact factor: 17.425

9.  Heritability of nonalcoholic fatty liver disease.

Authors:  Jeffrey B Schwimmer; Manuel A Celedon; Joel E Lavine; Rany Salem; Nzali Campbell; Nicholas J Schork; Masoud Shiehmorteza; Takeshi Yokoo; Alyssa Chavez; Michael S Middleton; Claude B Sirlin
Journal:  Gastroenterology       Date:  2009-01-25       Impact factor: 22.682

10.  Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study.

Authors:  Hyeon Chang Kim; Chung Mo Nam; Sun Ha Jee; Kwang Hyub Han; Dae Kyu Oh; Il Suh
Journal:  BMJ       Date:  2004-03-17
View more
  124 in total

1.  Intensive lifestyle treatment for non-alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment.

Authors:  B G P Koot; O H van der Baan-Slootweg; S Vinke; A E Bohte; C L J Tamminga-Smeulders; P L M Jansen; J Stoker; M A Benninga
Journal:  Int J Obes (Lond)       Date:  2015-08-28       Impact factor: 5.095

2.  Edmonton obesity staging system among pediatric patients: a validation and obesogenic risk factor analysis.

Authors:  M G Grammatikopoulou; M Chourdakis; K Gkiouras; P Roumeli; D Poulimeneas; E Apostolidou; I Chountalas; I Tirodimos; O Filippou; S Papadakou-Lagogianni; T Dardavessis
Journal:  J Endocrinol Invest       Date:  2018-01-08       Impact factor: 4.256

Review 3.  Fatty liver in childhood.

Authors:  Yesim Ozturk; Ozlem Bekem Soylu
Journal:  World J Hepatol       Date:  2014-01-27

4.  Predicting hepatic steatosis in a racially and ethnically diverse cohort of adolescent girls.

Authors:  Jennifer L Rehm; Ellen L Connor; Peter M Wolfgram; Jens C Eickhoff; Scott B Reeder; David B Allen
Journal:  J Pediatr       Date:  2014-05-22       Impact factor: 4.406

5.  Associations of Early to Mid-Childhood Adiposity with Elevated Mid-Childhood Alanine Aminotransferase Levels in the Project Viva Cohort.

Authors:  Jennifer A Woo Baidal; Erin E Elbel; Joel E Lavine; Sheryl L Rifas-Shiman; Matthew W Gillman; Emily Oken; Elsie M Taveras
Journal:  J Pediatr       Date:  2018-04-04       Impact factor: 4.406

6.  Identifying Predictors of Response to Vitamin E for the Treatment of Pediatric Nonalcoholic Steatohepatitis.

Authors:  Toshifumi Yodoshi; Sarah Orkin; Ana Catalina Arce-Clachar; Kristin Bramlage; Weizhe Su; Lin Fei; Stavra A Xanthakos; Marialena Mouzaki
Journal:  JPEN J Parenter Enteral Nutr       Date:  2020-01-27       Impact factor: 4.016

7.  Screening for non-alcoholic fatty liver disease in children and adolescents with type 1 diabetes mellitus: a cross-sectional analysis.

Authors:  Sebastian Kummer; Dirk Klee; Gerald Kircheis; Michael Friedt; Joerg Schaper; Dieter Häussinger; Ertan Mayatepek; Thomas Meissner
Journal:  Eur J Pediatr       Date:  2017-02-17       Impact factor: 3.183

8.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Authors:  Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong
Journal:  Hepatology       Date:  2018-04       Impact factor: 17.425

9.  Proton density fat-fraction is an accurate biomarker of hepatic steatosis in adolescent girls and young women.

Authors:  Jennifer L Rehm; Peter M Wolfgram; Diego Hernando; Jens C Eickhoff; David B Allen; Scott B Reeder
Journal:  Eur Radiol       Date:  2015-04-28       Impact factor: 5.315

10.  Targeted hepatic sonography during clinic visits for detection of fatty liver in overweight children: a pilot study.

Authors:  Emily R Perito; Patrika M Tsai; Sarah Hawley; Robert H Lustig; Vickie A Feldstein
Journal:  J Ultrasound Med       Date:  2013-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.